IBS in Black Adults: Why It Gets Missed and How to Get Care

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction: the nerves connecting your gut and your brain misfire, so a normal bowel registers as pain and your bowel habits swing toward diarrhea, constipation, or both. The defining symptom is abdominal pain tied to bowel movements, recurring at least one day a week. It is real biology, it is common, and it is treatable. The problem for Black patients is not that the condition is rare. It is that the diagnosis often never comes.

IBS is one of the disorders of gut-brain interaction, formerly called functional GI disorders. The gut and brain trade signals constantly. In IBS those signals are amplified, so the gut becomes hypersensitive and its motility speeds up or slows down. That mechanism is why pain, bloating, and altered stools cluster together. The National Institute of Diabetes and Digestive and Kidney Diseases lists the core symptoms as abdominal pain linked to bowel movements plus a change in how often you go or how your stool looks.

IBS is not inflammatory bowel disease (IBD). IBD, which includes Crohn's disease and ulcerative colitis, causes physical inflammation and damage that show up on a colonoscopy or in blood and stool markers. IBS does not damage the bowel and is invisible on those tests. IBS is also not lactose intolerance, which is a specific failure to digest milk sugar and is confirmed with a breath test or by cutting dairy and watching symptoms resolve. The reason this distinction matters: telling these apart is exactly the step that gets skipped when a clinician waves off a Black patient's gut symptoms without a proper history.

IBS is sorted by your dominant stool pattern, because the subtype drives treatment. IBS-D is diarrhea-predominant: mostly loose or watery stools. IBS-C is constipation-predominant: mostly hard or lumpy stools. IBS-M is mixed, swinging between both. The common thread across all three is abdominal pain that changes when you have a bowel movement, often easing afterward, often worse with stress or after eating. If your only symptom is bloating with no pain tied to bowel habits, it may be a different condition, which is one more reason a real history matters more than a guess.

IBS is a positive diagnosis, not a diagnosis of exclusion. The American College of Gastroenterology's 2021 guideline says clinicians should use the symptom-based Rome IV criteria to make the call and start treatment, rather than ordering test after test. The Rome IV definition: recurrent abdominal pain at least one day per week over the last three months, associated with two or more of these, related to defecation, a change in stool frequency, or a change in stool form. Limited testing is appropriate: the ACG recommends checking blood work to rule out celiac disease in people with diarrhea symptoms and a stool test called fecal calprotectin to rule out IBD.

That positive-diagnosis approach is meant to spare you a parade of invasive tests. For Black patients the risk runs in two directions at once. Some get over-tested while no one names the actual condition. Others get the opposite: symptoms dismissed, no workup at all, and a serious disease missed. The fix is not more random tests. It is a clinician who applies the criteria and knows which symptoms demand escalation.

The diagnostic gap is documented. In a 2026 study in Clinical Gastroenterology and Hepatology drawing on more than 88,000 US adults, among people who met Rome IV criteria for IBS, 35.0% of White respondents had received an IBS diagnosis from a clinician compared with 24.6% of Black respondents. Healthcare-seeking was comparable across racial groups, so the gap was not because Black patients sought care less. The authors point to clinical recognition and bias, not patient behavior.

The gap does not close at diagnosis. A 2024 study in Neurogastroenterology & Motility compared 301 Black and 301 White patients with IBS and found Black patients were less likely to be referred to a dietitian within a year of diagnosis, and less likely to arrive at their first visit already started on a neuromodulator, a class of nerve-targeting drugs used for IBS pain. Dietary coaching and these medications are front-line tools, so being routed away from them means worse symptom control. Missing the diagnosis and then under-treating it compound each other.

That second number is the danger of under-evaluation in hard numbers. A 2022 meta-analysis of more than a million people found colorectal cancer was detected far more often in the first year after an IBS label, then the excess vanished. The early spike is cancer that was already there and initially mislabeled as IBS. The lesson is not that IBS causes cancer. It is that an IBS label slapped on without checking the red flags can bury a cancer or an IBD that was waiting to be found, and Black adults face higher colorectal cancer death rates, which raises the stakes on getting that step right.

IBS responds to a layered plan covering diet, the gut-brain link, and medication matched to your subtype.

Diet, coached not guessed. The ACG endorses a limited trial of a low-FODMAP diet to improve overall symptoms. FODMAPs are fermentable carbohydrates that feed gas and draw water into the gut. A proper low-FODMAP trial is a structured three-phase process (strict elimination, methodical reintroduction, then a personalized long-term diet) run with a dietitian, not a permanent ban on entire food groups. Done alone and indefinitely it can wreck nutrition and your relationship with food. This is exactly the referral Black patients are less likely to receive, so it is worth asking for by name. Fiber helps too, but the type matters: soluble fiber such as psyllium can ease symptoms, while insoluble fiber such as wheat bran can make them worse.

The gut-brain connection and stress. Calling IBS a disorder of gut-brain interaction is not code for "it's in your head." The wiring between gut and brain is physical, and stress amplifies the signal. The ACG recommends gut-directed psychological therapies, including cognitive behavioral therapy and gut-directed hypnotherapy, for overall symptom control. If anxiety is driving flares, treating it is part of treating the gut, not a distraction from it. Our guide to anxiety symptoms in Black adults covers how anxiety shows up and gets care.

Medication by subtype. Prescription options are matched to your pattern. For IBS-C, the FDA-approved drugs linaclotide (Linzess), plecanatide (Trulance), and lubiprostone (Amitiza) draw fluid into the gut to ease constipation and pain. For IBS-D, rifaximin (Xifaxan), a gut-targeted antibiotic, and eluxadoline (Viberzi) are FDA-approved. Neuromodulators at low doses can quiet gut pain across subtypes. Over-the-counter antispasmodics and peppermint oil help some people with cramping, though the ACG notes the evidence for antispasmodics on overall symptoms is weak. Reflux can overlap with upper-gut symptoms; if heartburn is also in the picture, see our guide to GERD and acid reflux in Black adults.

Start with a clinician who will take a full history and apply the Rome IV criteria instead of dismissing you. Bring a one-week symptom log: when pain hits, what your stools look like, what you ate, and what you were doing. Ask three questions directly. Do I meet the Rome IV criteria for IBS? Do I have any alarm features that need a colonoscopy or other workup? Can I get a referral to a dietitian for a coached low-FODMAP trial? Push for a gastroenterology referral if your symptoms are not controlled, if you have any red flag, or if you are being brushed off without a plan. You can find a Black gastroenterologist or primary care clinician in our directory who will hear you out and run the right evaluation.